Clinical Trials Browser

INDUSTRY × Interventional × ZD4054 × Clear all

NCT00554229 2016-02-08

ENTHUSE M1

Phase 3 Completed

896 enrolled 15 charts

Prostatic Neoplasms

NCT00314782 2013-03-12

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Phase 1 Completed

Prostatic Neoplasms

NCT00090363 2013-01-08

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Phase 2 Completed

447 enrolled 13 charts

Prostatic Neoplasms

NCT00055471 2012-10-31

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Phase 2 Completed

22 enrolled 17 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00617669 2012-09-10

ENTHUSE M1C

Phase 3 Completed

1,494 enrolled 14 charts

Prostatic Neoplasms

NCT00626548 2012-09-03

ENTHUSE M0

Phase 3 Terminated

2,577 enrolled 8 charts

Prostatic Neoplasms

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Phase 2 Terminated

120 enrolled 8 charts

Hypersensitivity, Neoplasms

NCT00745875 2012-06-06

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Phase 2 Completed

66 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00997945 2011-05-19

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Phase 1 Completed

Advanced Solid Malignancies